Last reviewed · How we verify
AD036
AD036 is a small molecule that targets the orexin receptor to treat narcolepsy.
AD036 is a small molecule that targets the orexin receptor to treat narcolepsy. Used for Narcolepsy.
At a glance
| Generic name | AD036 |
|---|---|
| Also known as | 25/5, 75/1.5, 75/5 |
| Sponsor | Apnimed |
| Drug class | orexin receptor antagonist |
| Target | orexin receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
AD036 works by selectively blocking the orexin receptor, which is involved in the regulation of sleep-wake cycles. This leads to increased wakefulness and improved quality of life for patients with narcolepsy. By targeting this specific receptor, AD036 aims to provide a more targeted and effective treatment for this condition.
Approved indications
- Narcolepsy
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- Crossover Trial of AD036 in Obstructive Sleep Apnea (PHASE2)
- Trial of AD036 in Obstructive Sleep Apnea (PHASE2)
- Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD036 CI brief — competitive landscape report
- AD036 updates RSS · CI watch RSS
- Apnimed portfolio CI